NCT02967133 - A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Non-Small-Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Nonsmall Cell Lung CancerNon Small Cell Lung Cancer Recurrent

Interventions

DRUG

Nivolumab

"Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated."

DRUG

nab-paclitaxel

Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.

Trial Locations (4)

41017

St. Elizabeth's Healthcare, Edgewood

55416

Metro Minnesota community oncology research consortium, Saint Louis Park

63131

Missouri Baptist Medical Center, St Louis

68114

Nebraska Methodist Hospital, Omaha